谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

A First-in-human (FIH), Phase 1/2, Dose-Escalation, Dose-Optimization, and Dose-Expansion Study of PARP1-selective Inhibitor IMP1734 in Participants with Advanced Solid Tumors.

Guru P. Sonpavde,Justin A. Call,Gerald Steven Falchook,Benjamin Garmezy,Drew W. Rasco, Lan Liu, Tiantian Niu, Jenna He,Congcong Zhang,Jarema Kochan, Sam Rebello, Giuseppe Russo,Viola Chen,Suba Krishnan

Journal of Clinical Oncology（2024）

引用 0|浏览6
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要